Seven Fleet Capital Management LP Boosts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Seven Fleet Capital Management LP lifted its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 197.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,800 shares of the company’s stock after buying an additional 17,800 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Structure Therapeutics were worth $1,442,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of GPCR. Wellington Management Group LLP raised its holdings in Structure Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after acquiring an additional 119,146 shares during the period. Avoro Capital Advisors LLC grew its position in shares of Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after purchasing an additional 1,150,000 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Structure Therapeutics by 5.2% in the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after purchasing an additional 264,833 shares in the last quarter. BVF Inc. IL raised its stake in shares of Structure Therapeutics by 8.6% during the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after purchasing an additional 275,105 shares during the period. Finally, Morgan Stanley raised its stake in shares of Structure Therapeutics by 261.4% during the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after purchasing an additional 1,510,093 shares during the period. 91.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GPCR shares. Citizens Jmp lowered their price target on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a report on Friday, August 7th. HC Wainwright cut their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 17th. Finally, Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research report on Friday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $49.35 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a one year low of $18.26 and a one year high of $94.90. The company’s 50-day simple moving average is $50.65 and its 200 day simple moving average is $50.70. The firm has a market capitalization of $3.44 billion, a P/E ratio of -49.35 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.84 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.